PARGY-LAD
| Summary sheet: PARGY-LAD |
| PARGY-LAD | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||
| Common names | PARGY-LAD | ||||||||||||||||||||||||
| Substitutive name | 6-propynyl-6-nor-lysergic acid diethylamide,[1] N-Propynyl-nor-LSD,[1] N,N-Diethyl-6-propargyl-6-norlysergamide[1] | ||||||||||||||||||||||||
| Systematic name | (8β)-N,N-Diethyl-6-(prop-2-yn-1-yl)-9,10-didehydroergoline-8-carboxamide | ||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||
| Psychoactive class | Psychedelic | ||||||||||||||||||||||||
| Chemical class | Lysergamide | ||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||
|
|||||||||||||||||||||||||
| Interactions | |||||||||||||||||||||||||
| Cannabis | |||||||||||||||||||||||||
| Stimulants | |||||||||||||||||||||||||
| Tramadol | |||||||||||||||||||||||||
| Lithium | |||||||||||||||||||||||||
6-Propynyl-6-nor- Lysergic acid diethylamide (also known as N-Propynylnorlysergic acid N,N-diethylamide[1], N-PropynylnorLSD[1] or simply PARGY-LAD[1]) is a novel synthetic psychedelic substance of the lysergamide chemical class that produces a similar albeit significantly less distinct array of LSD-like psychedelic effects when administered. It is a close structural homolog of LSD known mainly for its obscurity and lack of distinguishing features.[1]
PARGY-LAD was first briefly mentioned as an analog of LSD by Alexander Shulgin in his book TiHKAL ("Tryptamines I Have Known and Loved"). It has been reported to be significantly less potent than LSD itself with "some activity reported at 160 μg" and "full activity at 500 micrograms."[2]
Very little data exists about the pharmacological properties, metabolism, and toxicity of PARGY-LAD, and it has very little history of human usage. It has recently appeared on the market alongside research chemical psychedelic lysergamides such as AL-LAD, ETH-LAD and PRO-LAD as a legal, grey-market alternative to LSD, and commercially distributed through online research chemical vendors, and is considered to be one of the least popular and available in the series. It is highly advised to approach this unstudied hallucinogenic substance with the proper amount of precaution and harm reduction practices if choosing to use it.
Chemistry
PARGY-LAD, or 6-propynyl-6-nor-lysergic acid diethylamide, is a synthetic alkaloid of the lysergamide family. PARGY-LAD is a structural analog of lysergic acid, with an N,N-diethylamide functional group bound to RN of the chemical structure. This core polycyclic structure is an ergoline derivative, and has overlapping tryptamine and phenethylamine groups embedded within it (although it is principally classed as a tryptamine).
PARGY-LAD's structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). Unlike LSD, PARGY-LAD does not contain a methyl group substituted at R6 of its nor-lysergic acid skeleton, this is represented by the nor- prefix. Instead, PARGY-LAD is substituted at R6 with a propynyl group.
Pharmacology
 |
This pharmacology section is incomplete. You can help by adding to it. |
PARGY-LAD likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from PARGY-LAD's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.
Subjective effects
 |
This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it. |
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects 
-
- Spontaneous physical sensations - Reports tend to characterize the "body high" of PARGY-LAD as prominent in comparison to its accompanying visual and cognitive effects. Like LSD, it can behave as a fast-moving, sharp and location specific or generalized tingling sensation, although this feeling is not necessarily pleasant and often manifests in a neutral way. For some, it is manifested spontaneously at different, unpredictable points throughout the trip, but for most, it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached.
- Physical euphoria - This component can occur with the development of spontaneous bodily sensations, and usually occurs at the peak or in wave-like bursts.
- Stimulation
- Bodily control enhancement
- Stamina enhancement - This component is generally mild in comparison to traditional stimulants.
- Headaches
- Nausea
- Appetite suppression
- Dehydration
- Difficulty urinating or Frequent urination
- Temperature regulation suppression
- Increased blood pressure
- Increased heart rate
- Increased perspiration
- Muscle contractions
- Muscle cramps
- Muscle spasms
- Olfactory hallucination
- Mouth numbing
- Excessive yawning
- Watery eyes
- Pupil dilation
- Vasoconstriction[citation needed]
- Wakefulness
- Teeth grinding - This component is considerably less intense when compared with that of substances like MDMA.
- Seizure - This is an effect whose likelihood is largely extrapolated from the seizures that have been reported from the use of LSD. They are thought to mainly be a risk in those who are genetically predisposed to them, particularly while accompanied by physically taxing conditions such as states of dehydration, fatigue or undernourishment. The extent to which this differs from the seizure risk posed by LSD is totally unknown; however, it should be noted that there are no documented cases of seizures occurring with this compound to date.[citation needed]
- Spontaneous physical sensations - Reports tend to characterize the "body high" of PARGY-LAD as prominent in comparison to its accompanying visual and cognitive effects. Like LSD, it can behave as a fast-moving, sharp and location specific or generalized tingling sensation, although this feeling is not necessarily pleasant and often manifests in a neutral way. For some, it is manifested spontaneously at different, unpredictable points throughout the trip, but for most, it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached.
Visual effects 
-
Enhancements
Distortions
- Drifting (melting, breathing, morphing and flowing)
- Brightness alteration
- Colour shifting
- Depth perception distortions
- Tracers
- After images
- Diffraction
- Perspective distortions
- Symmetrical texture repetition
Geometry
The visual geometry that is commonly present throughout this trip can be generally described as more similar in appearance to that of MET or 2C-B than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, structured in organization, brightly lit, colourful in scheme, synthetic in feel, multicoloured in scheme, flat in shading, sharp in edges, large in size, fast in speed, smooth in motion, angular in its corners, immersive in-depth and consistent in intensity. At higher dosages, it may almost consistently result in states of Level 8A or Level 8B visual geometry.[citation needed]
Hallucinatory states
Cognitive effects 
-
The cognitive effects of PARGY-LAD can be broken down into several components which progressively intensify proportional to dosage. In comparison to other psychedelics such as psilocybin, AL-LAD and mescaline, PARGY-LAD is likely able to be described as significantly more stimulating and fast-paced in terms of the specific style of thought stream(s) produced and contains a large number of potential effects.
The most prominent of these cognitive effects generally include:
- Analysis enhancement
- Anxiety & Paranoia
- Personal bias suppression
- Novelty enhancement
- Conceptual thinking
- Introspection
- Immersion enhancement
- Novelty enhancement
- Increased music appreciation
- Increased sense of humor
- Thought acceleration
- Thought connectivity
- Thought loops
- Language suppression
- Memory suppression
- Confusion
- Déjà vu
- Time distortion - This component has been reported to be particularly pronounced relative to other psychedelics.
- Wakefulness
Auditory effects 
Multi-sensory effects 
-
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
Transpersonal effects 
- It should be noted that these effects are the rarest and least reproducible those that can occur during a psychedelic experience. They are considered unique in that that simply taking more of the substance does not necessarily increase the chance they will occur, and are said to rely more on contextual factors such as the user's set and setting rather than the substance or dose itself. Their fullest manifestations are sometimes called "peak", "transcendent" or "transformative" experiences; however, they can still occur on a conceptual or cognitive level that can leave a lasting positive impact on the user.
Combinations
- Cannabis - When used in conjunction with cannabis, both the visual and cognitive effects of PARGY-LAD can be intensified and extended with extreme efficiency. This should be used with caution if one is not experienced with psychedelics. Many users sometimes report a dramatically more intense visual trip when combining it with THC concentrates such as hashish as opposed to cannabis flower. However, this can also amplify the anxiety, confusion and psychosis producing aspects of both substances significantly, so extreme caution with this combination is advised.
- Dissociatives - When used in combination with dissociatives, the geometry, euphoria, dissociation and hallucinatory effects are often greatly enhanced. Dissociative-induced holes, spaces, and voids while under the influence of PARGY-LAD have significantly more vivid visuals than dissociatives alone present, and more intense internal hallucinations and confusion.
- Alcohol - This interaction is not typically recommended due to alcohol’s ability to cause dehydration, nausea, and physical fatigue which can negatively affect a trip if taken in in moderate to dosages. This combination is however reasonably safe in low doses and when used responsibly, this can often take the edge off a trip as well as dull its psychedelic effects in a fashion somewhat similar to benzodiazepines, albeit more stressful on the body.
- Benzodiazepines - When used in combination with benzodiazepines, benzodiazepines can, depending on the dosage, slightly to completely reduce the intensity of the cognitive, physical and visual effects of a PARGY-LAD trip. They are very efficient at stopping bad trips at the cost of amnesia and reduced trip intensity. Caution is advised when acquiring them for this purpose due to the very high addiction potential that benzodiazepines possess.
- Psychedelics - When used in combination with other psychedelics, each substance's physical, cognitive and visual effects intensify and synergize strongly. The synergy between those substances is unpredictable, and for this reason generally not advised. If choosing to combine psychedelics, it is recommended to start with lower dosages than one would take for either substance individually.
Toxicity and harm potential
The toxicity and long-term health effects of recreational PARGY-LAD do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because PARGY-LAD is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried PARGY-LAD suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
While no formal studies have been conducted, PARGY-LAD is likely not habit-forming and it is reasonable to speculate that the desire to use it can actually decrease with repeated administration. As with most psychedelics, it likely possesses what is considered an intrinsic, self-regulating aspect to it.
Tolerance to the effects of PARGY-LAD is built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). PARGY-LAD presents cross-tolerance with all psychedelics, meaning that after the consumption of PARGY-LAD all psychedelics will have a reduced effect.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of PARGY-LAD. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
- Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.[citation needed]
- Tramadol - Tramadol is well-documented to lower the seizure threshold[3] and psychedelics may act to trigger seizures in susceptible individuals.[citation needed]
Legal status
 |
This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
- Germany: PARGY-LAD is controlled under the NpSG (New Psychoactive Substances Act)[4] as of July 18, 2019.[5] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[6]
- Latvia: PARGY-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.[7]
- Switzerland: PARGY-LAD is not specifically named under Buchstabe A, B, C and D. It is also not controlled as a defined derivative of Lysergic Acid under Verzeichnis E point 263 due to its alkynyl substitution which is not included. It can be considered legal.
- United Kingdom: As of January 7, 2015, PARGY-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.[8]
See also
External links
Literature
- Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409. https://doi.org/10.1007/BF02245940.
- Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
- Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Explore PARGY-LAD". TiHKAL · info. Isomer Design. Retrieved January 7, 2020.
- ↑ Shulgin, Alexander; Shulgin, Ann (1997). "#51. PRO-LAD". TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
- ↑ Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
- ↑ "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- ↑ "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
- ↑ "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- ↑ "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
- ↑ Advisory Council on the Misuse of Drugs (ACMD) (June 10, 2014). "Update of the generic definition for tryptamines" (PDF). Government Digital Service. p. 12. Retrieved January 1, 2020.